Table 2 Baseline characteristics of patients in 2 mg and 4 mg groups before and after propensity score matching
Before matching | After matching | |||||
|---|---|---|---|---|---|---|
2 mg | 4 mg | P value | 2 mg | 4 mg | P value | |
Number of cases | 53 | 86 | 33 | 33 | ||
Age (y) | 61.3 ± 12.1 | 57.4 ± 15.5 | 0.106 | 59.2 ± 11.8 | 59.5 ± 14.6 | 0.934 |
Sex | 46 women; 7 men | 69 women; 17 men | 0.306 | 26 women; 7 men | 25 women; 8 men | 0.769 |
Height (cm) | 154.2 ± 9.8 | 153.4 ± 7.8 | 0.425 | 153.2 ± 6.7 | 155.2 ± 4.8 | 0.798 |
Weight (kg) | 55.7 ± 9.8 | 56.8 ± 10.2 | 0.582 | 55.7 ± 9.4 | 56.2 ± 9.2 | 0.824 |
BMI (kg/m2) | 22.9 ± 3.29 | 23.0 ± 3.40 | 0.84 | 23.2 ± 3.19 | 22.9 ± 2.80 | 0.756 |
Disease duration (years) (± SD) | 15.4 ± 12.0 | 9.9 ± 8.5 | 0.004* | 11.6 ± 8.4 | 11.3 ± 8.2 | 0.868 |
Tender joint count (out of 28 joints) | 4.2 ± 3.5 | 5.0 ± 5.5 | 0.28 | 3.7 ± 2.9 | 3.0 ± 3.3 | 0.365 |
Swollen joint count (out of 28 joints) | 2.8 ± 3.1 | 2.6 ± 2.4 | 0.77 | 2.3 ± 2.7 | 2.3 ± 2.0 | 0.958 |
CRP (mg/dl) | 1.8 ± 2.2 | 1.4 ± 2.5 | 0.405 | 1.5 ± 1.6 | 1.4 ± 2.9 | 0.938 |
Physician VAS (± SD) | 42.8 ± 21.7 | 38.5 ± 23.0 | 0.289 | 38.1 ± 20.0 | 32.5 ± 22.6 | 0.289 |
Patient VAS (± SD) | 46.3 ± 25.7 | 44.3 ± 26.8 | 0.669 | 43.7 ± 26.8 | 36.9 ± 27.5 | 0.316 |
CDAI | 15.8 ± 8.0 | 15.8 ± 9.6 | 0.98 | 14.2 ± 7.8 | 12.3 ± 7.6 | 0.311 |
SDAI | 17.6 ± 9.3 | 17.3 ± 10.1 | 0.853 | 15.6 ± 8.3 | 13.7 ± 8.5 | 0.349 |
MTX Dosage (mg/week) | 3.9 ± 4.0 | 5.8 ± 5.0 | 0.017* | 4.4 ± 4.3 | 5.9 ± 4.6 | 0.163 |
PSL dosage (mg/day) | 2.9 ± 2.8 | 2.5 ± 3.4 | 0.44 | 3.0 ± 2.8 | 2.4 ± 3.5 | 0.395 |
Rheumatoid factor positive rate | 74.8 | 71.9 | 0.66 | 73.8 | 72.2 | 0.662 |
Anti-CCP antibody positive rate (%) | 50.4 | 75.6 | 0.0453* | 72.7 | 78.8 | 0.566 |
BIO use history: 1 drug | 11 | 23 | 6 | 12 | ||
BIO use history: 2 drugs | 10 | 20 | 6 | 9 | ||
BIO use history: 3 or more drugs | 17 | 30 | 11 | 5 | ||
eGFR | 46.3 ± 12.9 | 79.1 ± 17.2 | 43.6 ± 14.2 | 82.1 ± 20.4 | ||